Last reviewed · How we verify
Azithromycin 3 days
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acute bacterial infections (respiratory tract infections, otitis media, sinusitis), Sexually transmitted infections (chlamydia, gonorrhea), Community-acquired pneumonia.
At a glance
| Generic name | Azithromycin 3 days |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits peptide translocation, preventing the formation of the initiation complex and blocking protein synthesis. This bacteriostatic action stops bacterial growth and reproduction. The 3-day formulation refers to a shortened treatment course, typically used for acute infections where efficacy has been demonstrated over this condensed timeframe.
Approved indications
- Acute bacterial infections (respiratory tract infections, otitis media, sinusitis)
- Sexually transmitted infections (chlamydia, gonorrhea)
- Community-acquired pneumonia
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Vaginitis
- QT prolongation
- Allergic reactions
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Antibiotic Treatment of Recurrent Episodes of Asthma in Children (PHASE2)
- Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) (PHASE4)
- Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (PHASE2)
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children (PHASE3)
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin 3 days CI brief — competitive landscape report
- Azithromycin 3 days updates RSS · CI watch RSS
- University of Oxford portfolio CI